Europe Cervical Cancer Diagnostic Testing Market Dynamics and Trends by 2028

The Europe cervical cancer diagnostic testing market is expected to grow from US$ 1,368.86 million in 2021 to US$ 1,881.38 million by 2028; it is estimated to grow at a CAGR of 4.6% from 2021 to 2028.

Precancerous changes can delay the disease progression, thus offering an extended time window for its treatment. However, due to a lack of awareness or access to diagnostic services, many cases are detected in the later stages of illness. Human papillomavirus (HPV), typically transmitted through sexual contact, is one of the primary causes of cervical cancer. Out of more than 100 HPV strains reported, 13 are high-risk or carcinogenic strains. The HPV test detects human papillomavirus in cervical cells. The active gene E6 or E7 determines whether an HPV strain is of high or low risk. Other screening methods employed in low-resource areas of several countries include HPV DNA testing and visual inspection. Cervical screening on a regular basis aid in the early detection of cervical cancer, lowering the mortality rate from the disease. According to National Cancer Institute, most women belonging to the age group 21–65 should undergo the Pap test while women from the age group 30–65 should undergo the Pap and HPV tests every three years. In terms of revenue, the HPV test dominates the cervical cancer screening market, and this trend is expected to continue during the forecast period, thereby driving the Europe market growth.In case of COVID-19, Europe is highly affected specially the UK. The epidemic has caused a reduction in various medical procedures such as screening, follow-up, HPV triage tests, invasive diagnostic, and treatment of cervix-related indications. There is a need to create awareness among women about the advantages of early cervical cancer screening. The unwillingness of the patients to take the test is expected to have an undesired impact on the market in the region. However, global players such as Hologic Inc. in November 2021 launched Genius Digital Diagnostics System and are now commercially available in Europe. Thus, such active involvement of the international market players in the regional markets is expected to positively impact the region's market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe cervical cancer diagnostic testing market. The Europe cervical cancer diagnostic testing market is expected to grow at a good CAGR during the forecast period.   

Europe Cervical Cancer Diagnostic Testing Market Revenue and Forecast to 2028 (US$ Million)

Europe Cervical Cancer Diagnostic Testing Market Segmentation        

Europe Cervical Cancer Diagnostic Testing Market – By Type

• PAP Testing
• HPV Testing
• Colposcopy
• Cervical Biopsies
• Cystoscopy
• Others

Europe Cervical Cancer Diagnostic Testing Market – By Service Provider

• Diagnostics and Research Laboratories
• Hospitals and Clinics
• Specialty Clinics
• Home Care Services

Europe Cervical Cancer Diagnostic Testing Market, by Country

• Germany
• UK 
• France
• Italy
• Spain
• Rest of Europe

Europe Cervical Cancer Diagnostic Testing Market - Companies Mentioned

• Abbott
• BD
• Cooper Companies, Inc.
• DYSIS Medical Inc
• F. Hoffmann-La Roche Ltd.
• Femasys Inc.
• Guided Therapeutics, Inc
• Hologic, Inc.
• QIAGEN
• Quest Diagnostics Incorporated   

Europe Cervical Cancer Diagnostic Testing Report Scope